09/08/2026
A New Milestone in Rabies Prevention
SINOVAC is pleased to announce that its Serum-Free Rabies Vaccine for Human Use has received Drug Registration Certificate approval from China’s National Medical Products Administration (NMPA).
The vaccine is approved for both the conventional five-dose regimen and the WHO-recommended reduced four-dose post-exposure schedule.
🧬 Phase III clinical study highlights:
• 100% neutralizing antibody seroconversion at 14 days after the first dose and 3 months after vaccination
• >97.5% seroconversion maintained at 6 months
• No vaccine-related serious adverse events reported
• Manufactured using serum-free, animal component-free Vero cells
For Bangladesh, where timely access to effective rabies post-exposure prophylaxis remains an important public health priority, this advancement represents a potentially relevant development in rabies prevention.
🌏 Subject to applicable regulatory approvals and local requirements, SINOVAC will explore opportunities for future availability in Bangladesh and other international markets.
Advancing vaccine innovation. Strengthening protection against rabies.
BEIJING, China, August X, 2026 — SINOVAC announced that its Serum-Free Rabies Vaccine for Human Use has received a Drug Registration Certificate from China's National Medical Products Administrati